Capital/Financing Update • Jul 3, 2019
Capital/Financing Update
Open in ViewerOpens in native device viewer
PRESS RELEASE
Pursuant to the liquidity contract granted to Kepler Cheuvreux regarding Onxeo shares, the following resources were listed in the liquidity account as at June 30, 2019, settlement date:
During the 1st half of 2019, were negotiated a total of:
| BUY | 551,475 shares | €486,463.73 | 866 executions |
|---|---|---|---|
| SALE | 451,712 shares | €404,963.46 | 711 executions |
It is recalled that for the last half-year summary as at 31 December 2018, the following resources were included in the liquidity account:
It is also recalled that when the contract was set up on December 3, 2018, the following resources had been allocated to the liquidity account:
The liquidity agreement complies with AMF Decision n° 2018-01 dated 2nd July 2018, introducing liquidity agreements on equity securities as permitted market practice.
Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the soughtafter field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.
platON™ is Onxeo's proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company's product pipeline.
AsiDNA™, the first compound from platON™, is a first-in-class, highly differentiated DNA Damage Response (DDR) inhibitor based on a decoy and agonist mechanism acting upstream of multiple DDR pathways. Translational research has highlighted the distinctive properties of AsiDNA™, notably its ability to abrogate tumor resistance to PARP inhibitors regardless of the genetic mutation status, and its strong synergy with other tumor DNA-damaging agents such as chemotherapy and PARP inhibitors. The DRIIV-1 (DNA Repair Inhibitor-administered IntraVenously) phase I study has evaluated AsiDNA™ by systemic administration (IV) in advanced solid tumors and confirmed the active doses as well as a favorable human safety profile. The ongoing DRIIV-1b extension study is assessing the safety and efficacy of a 600 mg dose of AsiDNA™ in combination with carboplatin, and carboplatin and paclitaxel, in patients with solid tumors who are eligible for such treatments.
OX401 is a new drug candidate from platON™, optimized to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. In vivo preclinical proofof-concept data are expected early Q4 2019.
Onxeo's portfolio also includes belinostat, an HDAC inhibitor (epigenetics). Belinostat is already conditionally FDAapproved in the US as a 2nd line treatment for patients with peripheral T cell lymphoma and marketed in the US under the name Beleodaq® (belinostat IV form).
This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the section 5.5.1.4 "Risk Factors" ("Facteurs de Risque") of the 2016 reference document filed with the Autorité des marchés financiers on April 24, 2017 under number D.17-0423, which is available on the Autorité des marchés financiers website (www.amf-france.org) or on the Company's website (www.onxeo.com).
Onxeo Valerie Leroy, Investor Relations [email protected] +33 1 45 58 76 00
Media Relations Nicolas Merigeau NewCap [email protected] +33 1 44 71 94 98
Investor Relations / Strategic Communication Dušan Orešanský / Emmanuel Huynh NewCap [email protected] +33 1 44 71 94 92
Investor Relations US Brian Ritchie LifeSci Advisors [email protected] +1 212 915 2578
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.